Do affluent societies have the only options for the best therapy?
Gajewski
J L
JL
Robinson
P
P
D000293:Adolescent; D017668:Age of Onset; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D001549:Benzamides; D016026:Bone Marrow Transplantation / Q000191:economics; D002388:Catastrophic Illness / Q000191:economics; D002648:Child; D002681:China / Q000453:epidemiology; D019049:Developed Countries / Q000191:economics*; D003906:Developing Countries / Q000191:economics*; D016527:Drug Costs; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000191:economics; D017048:Health Care Costs; D015276:Health Care Rationing / Q000191:economics; D006297:Health Services Accessibility / Q000191:economics / Q000706:statistics & numerical data; D006806:Human Rights; D006801:Humans; D000068877:Imatinib Mesylate; D007182:Income; D007194:India / Q000453:epidemiology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000601:surgery; D008875:Middle Aged; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use; D012935:Social Justice; D013222:State Medicine / Q000191:economics; D013812:Therapeutics / Q000191:economics*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate